Skip to content
Screener

Omeros OMER Total Liabilities & Equity

Total Liabilities & Equity at other companies

Immunome logo
ImmunomeIMNM
$619.79M+80.9%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$363.79M-30.1%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$763.27M+198%
Annexon logo
AnnexonANNX
$262.89M-13.2%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$381.23M+118%
Vor Biopharma logo
Vor BiopharmaVOR
$506.75M+364%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$958.97M+245%
P/S10.7×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Omeros’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:07 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001437749-26-016720
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies (Note 10)
Shareholders’ deficit:
Preferred stock, par value $0.01 per share, 20,000,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025.
Common stock, par value $0.01 per share, 150,000,000 shares authorized at March 31, 2026 and December 31, 2025; 71,998,632 and 71,670,791 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively.720716
Additional paid-in capital793,581791,748
Accumulated deficit(857,635)(913,695)
Total shareholders’ deficit(63,334)(121,231)
Total liabilities and shareholders’ deficit$286,173$325,632

Document

FAQ

What is Omeros's total liabilities & equity?
Omeros (OMER) reported total liabilities & equity of $286.17M in Q1 2026.
How has Omeros's total liabilities & equity changed year-over-year?
Omeros's total liabilities & equity increased by 21.7% year-over-year, from $235.16M to $286.17M.
What is the long-term trend for Omeros's total liabilities & equity?
Over 5 years (2020 to 2025), Omeros's total liabilities & equity has grown at a 12.5% compound annual growth rate (CAGR), from $181.04M to $325.63M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Omeros's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude